Ripley94
08 Mar 2018
Re: bought today Dropped 10 fold since the buying shortly after IPO .Think Woodford still has it.
JefH
16 Jan 2018
Great news A big step this but patience still required before massive returns kick in
Nice to Michu
03 Jan 2018
Some upward movement at least but from an awfully low base... so even though the percents up in recent days look impressive most long term holders are still way way under water here .. so lots of upside potential, maybe..fortunately, having averaged down a few times recently on a small original position I'm nearly back to breakeven now... but I see this as 'potentially' very cheap still on a medium term view and so would at most sell a small part of holding around these levels.. Generally, with funding now sorted, hopefully possible news and actual news in first half of this year can drive this considerably.. but as ever such stocks are very risky ( but I was/am still in Immupharma too from the dark days and it has shown me that upside can be multi bagger in this space ...sometimes at least ..)
Nice to Michu
28 Sep 2017
Re: dog performance from this since I bought... ''of course you could perhaps alternatively say it may just have been that they knew of something bad coming instead'' INDEED and OUCH.. big capital raise today and taking on more debt too.. I'm going to wait a while now to watch how this plays out before I decide whether to buy more or not (my position is very small and so i'll likely add a small amoount to average down, in due course, I expect )
Nice to Michu
26 Sep 2017
dog performance from this since I bought but its at a cvery low level now versus historic comparison..Why is the big question:From a poster on LSE board: one reason for the most recent - of many - fall(s) may have been Hargreve Hale dumping a bunch - 500,000 for eg - incrementally recently .. and he thinks that might have been a function of its merger with Camacord.... (of course you could perhaps alternatively say it may just have been that they knew of something bad coming instead)He says that HH ongoing sale might also explain why the results have been held back.. ie let the selling finish first .... I was concerned about the extent of the fall - and indeed dumped some in 90's p fairly recently - but am a bit less concerned after that LSE post .. but still feel being careful is the way to go in case some bad news is coming in interims.. so I'm going to wait to see those interims this week before doing anything.. I will keenly examine these as if they are even half decent this could be said to be very cheap currently .. imho and of course DYOR
Antsy
20 Jul 2017
Re: Singers Note that you need to be a premium subscriber to access the content on Singer's Search Tree site 
(
Antsy
20 Jul 2017
Re: up 25%! Thank you for the update. It would be useful to have the target price too.
bigmacone
12 Jul 2017
Shares Investor Evening Pretty impressive presentation at the Shares Investor Evening last night.Any views on this as an investment?
Sambram
10 Aug 2016
Re: up 25%! Singers and Panmure updates on research tree:"This morning’s trading H1 update indicates revenue in line with our expectations. We continue to believe that Midatech is at an interesting juncture, with the FDA filing of Q-Octreotide (a long-acting formulation of somatostatin) expected in the second half of the year and clinical trials for the company’s glioblastoma programme MTR103 due to commence in 2017e. We also continue to expect the group’s US speciality pharma operations to be cash generative from 2017e on a stand-alone basis." - Singers"Trading and revenues for the first half are in-line with updated expectations following positive guidance within the company’s 2015 results statement and we maintain our full-year forecasts. First-half revenues are expected to be £3.80m (1H15 £0.32m). It has been a tremendously busy period for Midatech both in terms of pipeline development and in terms of commercial activities – we remind investors, particularly, of the US launch of Zuplenz in April – and we consider the gap between our target price and the current share price unduly discounts the value opportunity." - Panmure
Sambram
10 Aug 2016
up 25%! Good solid results, going in the right direction and should be cash generative by 2017 according to N1 Singer
Nice to Michu
29 Mar 2016
I'm in based on Woodford and low sp I have done minimal research here and so it's a flyer from me. I was light pharma and flipped a coin between this and Immupharma - which I'll buy too if it gets back around 20p - and here I am.Good luck to all holders
II Editor
30 Dec 2015
NEW ARTICLE: City legend’s share tips for 2016 "What are your favourite blue-chip shares and why? On a personal basis I'm not allowed to make stock recommendations, but I can tell you what the various people at Panmure Gordon recommend. There is a strong liking for technology and there are ..."[link]
paulmc1
23 Dec 2015
Re: Price Slide Another dip today - RNS re issue of shares (re Q Chip) but it doesn't appear to be particularly significant re dilution. And although these dips are certainly having a significant cumulative impact on the sp it's happening on tiny volumes and therefore seems to be more about drift than a change of actual sentiment/confidence.
paulmc1
19 Dec 2015
Re: Price Slide "...any thoughts?"Could be something not quite OK (or perceived) with the deal announced first thing Friday? Not a good reaction and so Panmure reaffirm a buy rec that morning (also pushed enthusiastically on their 2016 recs video on iii), and then later a director buy so modest you wonder if it was just to trigger the usual director buy coverage. Just trying to read between the lines though, no real knowledge - only on my watch list. ATB
5haggy
17 Dec 2015
Price Slide All very quiet on this Board - as usual!A near 15% slide in the SP so far this week and no comments, no RNS and no news!Anybody willing to step up to the plate with any thoughts?
